Author: Pradip Tikhe

The Arm2u biomedical engineering team, from the UPC’s Barcelona School of Industrial Engineering (ETSEIB), has designed and manufactured using 3D printing technology a customizable transradial prosthesis that responds to the user’s nerve impulses. Fifteen bachelor’s and master’s degree students from the Barcelona School of Industrial Engineering (ETSEIB) of the Universitat Politècnica de Catalunya · BarcelonaTech (UPC) share the same dream: improving the quality of life of people with disabilities using assistive technologies. Specifically, the young biomedical engineering team Arm2u is developing a transradial prosthesis—which replaces an arm missing below the elbow—with myoelectric control, i.e. controlled by the natural electrical signals…

Read More

The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on. For decades, Germany’s Fresenius Medical Care (FMC) (FMEG.DE) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function. 6 minute readOctober 5, 20223:52 PM GMT+5:30Last Updated an hour ago Fresenius taps pre-dialysis kidney care as drugs promise treatment change By Ludwig Burger 1/2 Diabetes drug Farxiga (dapagliflozin)…

Read More

Morningstar analysts recommend these biotech stocks. Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or two world-changing drugs or therapies for billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval from the U.S. Food and Drug Administration or other global drug regulators. The biotech group has struggled as a whole in 2022, but the Morningstar analyst team says the innovation that has always supported the biotech industry is alive and well. Here are eight of Morningstar’s top biotech stocks to buy.

Read More

Treatment involves adult patients with severe alopecia areata Eli Lilly has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for baricitinib – also known as Olumiant – for the treatment of severe alopecia areata in adult patients. Marketing authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both used the Severity of Alopecia Tool (SALT) score and both met the primary endpoint among the proportion of patients. Meanwhile, achievement of full regrowth or regrowth with minimal gaps in eyebrow and eyelash hair was also seen, with baricitinib, for patients who at baseline had significant…

Read More

Events will raise awareness around the impact of atopic dermatitis across cultures LEO Pharma, a leader in medical dermatology, today launched ‘AD Days Around the World’, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD), the most common form of eczema. AD is a chronic, inflammatory skin disease characterised by intense itch and eczematous lesions. The condition is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation. In collaboration with patient advocacy organisations in France, Italy, Germany and Spain, the campaign shares real patient stories to educate and inform…

Read More

Whenever cells are used to produce biotherapeutics such as antibodies, process impurities known as host cell proteins (HCPs) find their way into downstream product flows. Some HCPs are benign. Others are harmful. But which are which? There’s one way to know for certain: detect and assess all HCPs. Once the harmful HCPs are identified, they can be removed by introducing the appropriate purification measures. Typically, these measures are called upon to remove the vast majority of HCPs. Historically, most HCP monitoring served to affirm that bioprocesses remained stable, run after run. According to Eric Bishop, vice president of research and…

Read More